Arbutus Biopharma Corp. is a biopharmaceutical company, engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded on October 6, 2005 and is headquartered in Burnaby, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone604-419-3200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.90 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable
Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions
What is Arbutus Biopharma's stock symbol?
Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."
How were Arbutus Biopharma's earnings last quarter?
Arbutus Biopharma Corp (NASDAQ:ABUS) issued its quarterly earnings data on Thursday, March, 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.39) by $0.02. The biopharmaceutical company had revenue of $1.60 million for the quarter, compared to analyst estimates of $0.77 million. Arbutus Biopharma had a negative net margin of 986.23% and a negative return on equity of 74.52%. View Arbutus Biopharma's Earnings History.
When is Arbutus Biopharma's next earnings date?
What price target have analysts set for ABUS?
5 brokers have issued 1 year target prices for Arbutus Biopharma's stock. Their predictions range from $5.00 to $9.00. On average, they anticipate Arbutus Biopharma's share price to reach $6.8333 in the next year. This suggests a possible upside of 93.6% from the stock's current price. View Analyst Price Targets for Arbutus Biopharma.
What is the consensus analysts' recommendation for Arbutus Biopharma?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Arbutus Biopharma.
Has Arbutus Biopharma been receiving favorable news coverage?
Media headlines about ABUS stock have been trending somewhat negative recently, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arbutus Biopharma earned a coverage optimism score of -1.1 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of Arbutus Biopharma's key competitors?
Some companies that are related to Arbutus Biopharma include Eidos Therapeutics (EIDX), ANI Pharmaceuticals (ANIP), Rocket Pharmaceuticals (RCKT), Cara Therapeutics (CARA), CymaBay Therapeutics (CBAY), Revance Therapeutics (RVNC), Vectura Group (VEGPF), Intra-Cellular Therapies (ITCI), ZIOPHARM Oncology (ZIOP), Lexicon Pharmaceuticals (LXRX), Eagle Pharmaceuticals (EGRX), Evolus (EOLS), Magenta Therapeutics (MGTA), DiaMedica Therapeutics (DMCAF) and TG Therapeutics (TGTX).
What other stocks do shareholders of Arbutus Biopharma own?
Who are Arbutus Biopharma's key executives?
Arbutus Biopharma's management team includes the folowing people:
- Mark J. Murray, President, Chief Executive Officer & Director
- David C. Hastings, Chief Financial Officer
- Michael J. Sofia, Chief Scientific Officer
- Elizabeth Howard, Executive Vice President & General Counsel
- James Heyes, Vice President-Drug Delivery
Who are Arbutus Biopharma's major shareholders?
Arbutus Biopharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include RTW Investments LP (7.82%), Foresite Capital Management IV LLC (2.85%), Bank of Montreal Can (1.74%), Hudson Bay Capital Management LP (1.17%), Norges Bank (0.67%) and Northern Trust Corp (0.56%). View Institutional Ownership Trends for Arbutus Biopharma.
Which institutional investors are selling Arbutus Biopharma stock?
ABUS stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management IV LLC, Bank of New York Mellon Corp, SG Americas Securities LLC, Northern Trust Corp and D. E. Shaw & Co. Inc.. View Insider Buying and Selling for Arbutus Biopharma.
Which institutional investors are buying Arbutus Biopharma stock?
ABUS stock was acquired by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, Norges Bank, RTW Investments LP, Bailard Inc., Alps Advisors Inc., Bank of Montreal Can, Geode Capital Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Arbutus Biopharma.
How do I buy shares of Arbutus Biopharma?
Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arbutus Biopharma's stock price today?
One share of ABUS stock can currently be purchased for approximately $3.53.
How big of a company is Arbutus Biopharma?
Arbutus Biopharma has a market capitalization of $198.10 million and generates $5.90 million in revenue each year. The biopharmaceutical company earns $-57,060,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.
What is Arbutus Biopharma's official website?
How can I contact Arbutus Biopharma?
Arbutus Biopharma's mailing address is 100-8900 GLENLYON PARKWAY, BURNABY A1, V5J 5J8. The biopharmaceutical company can be reached via phone at 604-419-3200 or via email at [email protected]
MarketBeat Community Rating for Arbutus Biopharma (NASDAQ ABUS)
MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma and other stocks. Vote "Outperform" if you believe ABUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
